

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT

THE APPROVAL FOR THE ISSUANCE OF UNLISTED RMB DENOMINATED ORDINARY SHARES FROM THE CSRC

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

References are made to the announcement dated March 8, 2023, the circular dated April 12, 2023 and the announcement of poll results of the EGM and Class Meetings dated April 28, 2023 of the Company (the “**Relevant Announcements and Circulars**”) in relation to, among other things, the details of the Proposed Issuance of Unlisted RMB Denominated Ordinary Shares by the Company and its related matters. Unless otherwise stated, terms used in this announcement shall have the same meanings as those defined in the Relevant Announcements and Circulars.

The Company is pleased to announce that we have obtained the Approval for the Registration of Shares Issued by AIM Vaccine Co., Ltd. to Target Subscribers (Zheng Jian Xu Ke [2023] No. 1816) (the “**Approval**”) from the China Securities Regulatory Commission (the “**CSRC**”). The CSRC has approved the issuance of Unlisted RMB Denominated Ordinary Shares. Details of the Approval are as follows:

1. The application for registration of Shares issued by the Company to target subscribers is approved.
2. The issuance of the Company should be implemented strictly in accordance with the application documents submitted to the CSRC.
3. The Approval shall be valid for a period of 12 months from the date of approval for registration (i.e. August 17, 2023).
4. From the date of approval for registration to the completion of the issuance, if any significant matters occur to the Company, the Company shall report such matters to the CSRC in a timely manner and handle such matters in accordance with relevant regulations.

As at the date of this announcement, the details of the issuance plan for the issuance of Unlisted RMB Denominated Ordinary Shares have not been finalized. There remains uncertainty as to the issuance, as it is subject to the fulfillment of other pre-conditions referred to in the Relevant Announcements and Circulars.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, August 30, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.